---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-240624"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2023-09-22T23:59:59+00:00"
generated_at: "2026-06-10T09:39:46.184177+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics receives Nasdaq delisting notices for MVLS and bid price deficiencies

## Summary
- Notices: MVLS below $50M and bid price below $1.00 for 30 consecutive business days.
- Compliance deadline is March 20, 2024; 180-day cure period for both requirements.
- If not compliant, faces delisting; may appeal or transfer to Nasdaq Capital Market.
- Company will monitor and consider options but cannot assure compliance.

## SEC filing metadata
- accession: 0001193125-23-240624
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2023-09-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312523240624/0001193125-23-240624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312523240624/d551276d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-240624
- JSON: https://secwatch.observer/filing/0001193125-23-240624.json
- Plain text: https://secwatch.observer/filing/0001193125-23-240624.txt

## Key facts
- Listing & Compliance Notices
  Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: September 22, 2023, Galera Therapeutics, Inc. (the “Company”) received two written notices (the “Notices”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that (i) the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “Minimum MVLS Requirement”) and (ii) for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed bel
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312523240624/0001193125-23-240624-index.htm
- Listing & Compliance Notices
  Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A)
  source text: September 22, 2023, Galera Therapeutics, Inc. (the “Company”) received two written notices (the “Notices”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that (i) the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “Minimum MVLS Requirement”) and (ii) for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed bel
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312523240624/0001193125-23-240624-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.